Skip to Main Content

Paper Details

Once-weekly (70 mg/m ) vs twice-weekly (56 mg/m ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials.
Cancer Medicine
12
2020
CHAMPION, RRMM, bortezomib, carfilzomib, dexamethasone, multiple myeloma, patient, patients, relapsed and/or refractory multiple myeloma
Author NameAffiliation
Alexander Keith StewartMayo Clinic
David S SiegelJohn Theurer Cancer Center, Hackensack University Medical Center
  • 1 - 2

Datasets

Release 1.2